Abbott Laboratories (NYSE:ABT) registered a 0.10% increase, still its new closing price is 16.77% up from the company’s 1 year high of 45.21.It posted 1.33% gains in previous 5 sessions and is now the subject of 4 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 7 buy or better ratings. The 17 stock analysts following this company have an average price target at $46.85, with individual PT in the $41.00-$50.00 range. The shares moved at $41.00, implying that brokerage firms see shares gaining about 14.51% in twelve months time.

Abbott Laboratories (ABT) SEC Form 4 News

The stock is getting much attention these days as insiders are adding shares while they posted a 7.43% rise year to date. A Executive Vice President at Abbott Laboratories (ABT) acquired shares in a transaction closed on Tuesday December 20, 2016. Blaser Brian J bought 15,580 shares in the company at $38.45 each and collected $599,000 in proceeds. Blaser Brian J now owns 145,062 shares in the company after this transaction. A Executive Vice President in the company, Ford Robert B, disclosed a transaction on Wednesday December 14, 2016 that ended up paying $499,000 from the purchase of 12,775 shares at $39.09 per share.

Abbott Laboratories (NYSE:ABT) Upcoming Results on Tap

Abbott Laboratories will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $0.43 in that period. Sales during the quarter are predicted to arrive at $6.16 billion.

Earnings surprise history: Last quarter, the company posted approximately $5.33 billion in revenue and EPS of $0.65. The mean forecast was for $5.38 billion and $0.65 a share, respectively. One quarter earlier, revenue for the stock was at $5.3 billion, with earnings at $0.59/share.

Abbott Laboratories (ABT) Brokerage Update

Abbott Laboratories (ABT) is in Edward Jones’s research list so their analyst rating change is noteworthy. These shares were upgraded to Buy from Hold by Edward Jones, according to news reported on Tuesday June 21, 2016.Another important research note was issued by Morgan Stanley on Monday January 04, 2016.The firm downgraded ABT to Equal-Weight from Overweight. Over the last six months and over the last three months, the shares of Abbott Laboratories (ABT), have changed -6.58% and 3.27%, respectively.